Leustat Subcutaneous

Cladribine, the active ingredient in Leustat Subcutaneous, is an antimetabolite presented as a subcutaneous formulation for injection use. It is employed primarily in the treatment of hairy cell leukemia, targeting malignant lymphocytes to achieve disease control. GNH USA supplies Leustat Subcutaneous as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leustat Subcutaneous, a purine nucleoside analog, is used in hematologic malignancies that involve abnormal lymphocyte proliferation. - Hairy cell leukemia: induces remission by depleting malignant B‑cells and restoring normal hematopoiesis.

Cladribine may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Fever: transient elevations in body temperature. - Lymphopenia: reduction in lymphocyte count. - Anemia: decreased red blood cell levels. - Thrombocytopenia: lowered platelet counts.

Serious or Rare Side Effects: - Severe infections: opportunistic bacterial, viral, or fungal infections. - Secondary malignancies: rare development of new cancers. - Autoimmune disorders: emergence of autoimmune hemolytic anemia. - Hepatotoxicity: liver enzyme elevations. - Renal impairment: decreased kidney function in susceptible individuals.

Before initiating therapy with Leustat Subcutaneous, clinicians should assess patient suitability and monitor for potential complications. - Blood count monitoring: perform complete blood counts regularly to detect cytopenias. - Infection risk: screen for active infections and advise prophylactic measures. - Live vaccines: avoid administration during treatment and for several weeks after. - Pregnancy and lactation: use only if benefits outweigh potential fetal risks; discuss with obstetric specialist. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Cladribine can interact with other agents that affect immune function or hematopoiesis.

Major Interactions (Avoid): - Concurrent myelosuppressive chemotherapy: may exacerbate cytopenias. - Live attenuated vaccines: increased risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Antiviral agents (e.g., acyclovir): may require dose adjustment for renal clearance. - Immunosuppressants (e.g., azathioprine): monitor blood counts closely. - CYP450 substrates: cladribine is not a strong inducer/inhibitor, but monitor drugs with narrow therapeutic windows.